Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

522 Postmarket Surveillance Studies Database
  • Print
  • Share
  • E-mail
-
The FDA has the authority to require device manufacturers to perform postmarket surveillance under Section 522 of the Food, Drugs and Cosmetics (FD&C) Act, when questions are identified for devices that meet the statutory criteria. This database contains information about 522 Postmarket Surveillance Studies that have been required. This database allows you to search information about the postmarket surveillance requirements by manufacturer or device.

Learn more...

            
  To search for Manufacturer beginning with a specific letter, select that letter
 
 A 
 B 
 C 
 D 
 E 
 F 
 G 
 H 
 I 
 J 
 L 
 M 
 N 
 O 
 P 
 R 
 S 
 T 
 U 
 V 
 W 
 X 
 Z 
 
 
   

Sampling and Culturing Study


 
Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Delayed
522 Number / Requirement Number PS200003 / PSS001
Date Original Plan Accepted 04/17/2020
Date Current Plan Accepted 09/28/2022
Study Name Sampling and Culturing Study
Device Name Evis exera iii duodenovideoscope tjf-q190v
Root Document Number K193182 
General Study Protocol Parameters
Study Design Bench/Lab Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population
Detailed Study Protocol Parameters
Study Objectives This is a bench study in which clinically-used TJF-Q190V duodenoscopes will be sampled and cultured after reprocessing by trained healthcare facility staff using Olympus’ reprocessing instructions.
The study objectives are as follows:
1. To identify the percentage of clinically used duodenoscopes that remain contaminated with viable microorganisms after use of labeled reprocessing instructions.
2. For devices that remain contaminated after use of labeled reprocessing instructions, to determine the factors that contributed to microbial contamination and identify action items necessary to adequately decontaminate the devices.
Study Population The study population consists of Olympus TJF-Q190V duodenoscopes that have been used in ERCP procedures and reprocessed by trained healthcare facility staff in accordance with the duodenoscope reprocessing manual.
All duodenoscopes will be subjected to sampling following completion of the cleaning and manual disinfection, or disinfection using AERs listed on the FDA webpage (https://www.fda.gov/medical-devices/reprocessing-reusable-medical-devices/information-about-automated-endoscope-reprocessors-aers-and-fdas-evaluation).
Sample Size The study will include 850 properly collected samples from a minimum of 10 sites. These samples will be collected from a minimum of 85 scopes, with a maximum of 20 samples collected per scope. In addition, no more than 10% of all samples will be collected from brand new TJF-Q190V duodenoscopes, with the term “brand new” being defined as a duodenoscope that has never been used clinically.
Study Milestones:
- First sample collected by April 2021
- 20% of samples collected by July 2021
- 50% of samples collected by October 2021
- 100% of samples collected by January 2022
- Final Report submission by April 2022
Key Study Endpoints The primary endpoint is successful completion of duodenoscope sampling and culturing to determine real-world contamination rates, where samples are collected from clinically used duodenoscopes from healthcare facilities. Although the expectation is that none of the duodenoscope samples should be positive for high concern organisms or have >100 CFU of low/moderate concern organisms, a thorough investigation to identify the root causes of positive samples will be conducted for any positive sample, and risk mitigation strategies will be identified.


Sampling and Culturing Study Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
3 month report 07/17/2020 07/16/2020 On Time
6 month report 10/17/2020 10/19/2020 On Time
9 month report 01/17/2021 01/21/2021 On Time
1 year report 04/17/2021 04/19/2021 On Time
15 month report 07/16/2021 07/16/2021 On Time
18 month report 10/14/2021 10/15/2021 On Time
21 month report 01/12/2022 01/12/2022 On Time
24 month report 04/12/2022 04/07/2022 On Time
27 month report 07/12/2022 07/13/2022 On Time
30 month report 10/12/2022 10/12/2022 On Time
33 month report 01/12/2023 01/12/2023 On Time
36 month report 04/12/2023 04/14/2023 Overdue/Received
39 month report 07/12/2023 07/12/2023 On Time
final report 08/31/2023 08/31/2023 On Time


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources
-
-